Major bleeding during anticoagulation after cerebral ischemia: Patterns and risk factors

Neurology

Volumn 53, Issue 6, 1999, Pages 1319-1327

  Gorter, J W ^a,b   Algra, Ale ^a,b   Van Gijn, J ^b   Kappele, L J ^b   Koudstaal, P J ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anticoagulation; Atrial fibrillation; Cerebral ischemia; Hemorrhage; Leukoaraiosis; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING TENDENCY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; HEART ATRIUM FIBRILLATION; LEUKOARAIOSIS; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS PREVENTION; TREATMENT PLANNING;

EID: 0032862352     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.6.1319     Document Type: Article

References (26)

1. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342: 1255-1262.
2. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633-638.
3. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-152.
4. The Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980;2: 989-994.
5. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;353:499-503.
6. The EPSIM Research Group. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982;307:701-708.
7. The Stroke Prevention In Reversible Ischemia Trial (SPIRIT) Study Group. A random trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997;42:857-865.
8. The European Atrial Fibrillation Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333:5-10.
9. van Swieten JC, Hijdra A, Koudstaal PJ, van Gijn J. Grading white matter lesions on CT and MRI: a simple scale. J Neurol Neurosurg Psychiatry 1990;53:1080-1083.
10. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996;156:409-416.
11. Bamford J, Sandercock P, Jones L, Warlow C. The natural history of lacunar infarction: the Oxfordshire Community Stroke Project. Stroke 1987;18:545-551.
12. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-17.
13. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH, for the National Consortium of Anticoagulation Clinics. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996;124:970-979.
14. van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briët E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 1996;76:12-16.
15. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. Ann Intern Med 1993;118: 511-520.
16. Rosendaal FR, Cannegieter SC, van der Meer FJM, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-239.
17. Koudstaal PJ, van Gijn J, Lodder J, et al. Transient ischemic attacks with and without a relevant infarct on computed tomographic scans cannot be distinguished clinically. Arch Neurol 1991;48:916-920.
18. Hart RG, Bradley SB, Anderson DC. Oral anticoagulants and intracranial hemorrhage: facts and hypotheses. Stroke 1995; 26:1471-1477.
19. Caplan LR. Intracerebral haemorrhage. Lancet 1992;339: 656-658.
20. Fujii Y, Takeuchi S, Saski O, Minakawa T, Tanaka R. Multivariate analysis of predictors of hematoma enlargement in spontaneous intracerebral hemorrhage. Stroke 1998;29:1160-1166.
21. Cannegieter SC, Rosendaal FR, Bollen WLEM, Briët E. Risk factors for ischemic and hemorrhagic stroke in the anticoagulant treatment of patients with mechanical heart valve prostheses. Circulation 1994;89:635-641.
22. Rosendaal FR. The Scylla and Charybdis of oral anticoagulant treatment. Lancet 1996;335:587-598.
23. Mattle H, Kohler S, Huber P, Rohner M, Steinsiepe KF. Anticoagulation-related intracranial extracerebral haemorrhage. J Neurol Neurosurg Psychiatry 1989;52:829-837.
24. Kwa VIH, Franke CL, Verbeeten B Jr, Stam J, on behalf of the Amsterdam Vascular Medicine Group. Silent intracerebral microhemorrhage in patients with ischemic stroke. Ann Neurol 1998;44:372-377.
25. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke 1997;28:652-659.
26. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87: 144-152.